Factors in Variability of Serial Gabapentin Concentrations in Elderly Patients with Epilepsy

Jeannine M Conway, Lynn E Eberly, Joseph F. Collins, Flavia M. Macias, R. Eugene Ramsay, Ilo E Leppik, Angela K Birnbaum

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objectives: To characterize and quantify the variability of serial gabapentin concentrations in elderly patients with epilepsy. Methods: This study included 83 patients (age ≥ 60 yrs) from an 18-center randomized double-blind double-dummy parallel study from the Veterans Affairs Cooperative 428 Study. All patients were taking 1500 mg/day gabapentin. Within-person coefficient of variation (CV) in gabapentin concentrations, measured weekly to bimonthly for up to 52 weeks, then quarterly, was computed. Impact of patient characteristics on gabapentin concentrations (linear mixed model) and CV (linear regression) were estimated. Results: A total of 482 gabapentin concentration measurements were available for analysis. Gabapentin concentrations and intrapatient CVs ranged from 0.5 to 22.6 μg/ml (mean 7.9 μg/ml, standard deviation [SD] 4.1 μg/ml) and 2% to 79% (mean 27.9%, SD 15.3%), respectively, across all visits. Intrapatient CV was higher by 7.3% for those with a body mass index of ≥ 30 kg/m2 (coefficient = 7.3, p=0.04). CVs were on average 0.5% higher for each 1-unit higher CV in creatinine clearance (coefficient = 0.5, p=0.03) and 1.2% higher for each 1-hour longer mean time after dose (coefficient = 1.2, p=0.04). Conclusions: Substantial intrapatient variability in serial gabapentin concentration was noted in elderly patients with epilepsy. Creatinine clearance, time of sampling relative to dose, and obesity were found to be positively associated with variability.

Original languageEnglish (US)
Pages (from-to)1197-1203
Number of pages7
JournalPharmacotherapy
Volume37
Issue number10
DOIs
StatePublished - Oct 1 2017

Fingerprint

Epilepsy
Linear Models
Creatinine
Veterans
gabapentin
Body Mass Index
Obesity

Keywords

  • antiseizure drug
  • concentration
  • elderly
  • epilepsy
  • gabapentin
  • variability

Cite this

Factors in Variability of Serial Gabapentin Concentrations in Elderly Patients with Epilepsy. / Conway, Jeannine M; Eberly, Lynn E; Collins, Joseph F.; Macias, Flavia M.; Ramsay, R. Eugene; Leppik, Ilo E; Birnbaum, Angela K.

In: Pharmacotherapy, Vol. 37, No. 10, 01.10.2017, p. 1197-1203.

Research output: Contribution to journalArticle

@article{e71c9cdcf57f4decb3d22dd7fdae3c62,
title = "Factors in Variability of Serial Gabapentin Concentrations in Elderly Patients with Epilepsy",
abstract = "Objectives: To characterize and quantify the variability of serial gabapentin concentrations in elderly patients with epilepsy. Methods: This study included 83 patients (age ≥ 60 yrs) from an 18-center randomized double-blind double-dummy parallel study from the Veterans Affairs Cooperative 428 Study. All patients were taking 1500 mg/day gabapentin. Within-person coefficient of variation (CV) in gabapentin concentrations, measured weekly to bimonthly for up to 52 weeks, then quarterly, was computed. Impact of patient characteristics on gabapentin concentrations (linear mixed model) and CV (linear regression) were estimated. Results: A total of 482 gabapentin concentration measurements were available for analysis. Gabapentin concentrations and intrapatient CVs ranged from 0.5 to 22.6 μg/ml (mean 7.9 μg/ml, standard deviation [SD] 4.1 μg/ml) and 2{\%} to 79{\%} (mean 27.9{\%}, SD 15.3{\%}), respectively, across all visits. Intrapatient CV was higher by 7.3{\%} for those with a body mass index of ≥ 30 kg/m2 (coefficient = 7.3, p=0.04). CVs were on average 0.5{\%} higher for each 1-unit higher CV in creatinine clearance (coefficient = 0.5, p=0.03) and 1.2{\%} higher for each 1-hour longer mean time after dose (coefficient = 1.2, p=0.04). Conclusions: Substantial intrapatient variability in serial gabapentin concentration was noted in elderly patients with epilepsy. Creatinine clearance, time of sampling relative to dose, and obesity were found to be positively associated with variability.",
keywords = "antiseizure drug, concentration, elderly, epilepsy, gabapentin, variability",
author = "Conway, {Jeannine M} and Eberly, {Lynn E} and Collins, {Joseph F.} and Macias, {Flavia M.} and Ramsay, {R. Eugene} and Leppik, {Ilo E} and Birnbaum, {Angela K}",
year = "2017",
month = "10",
day = "1",
doi = "10.1002/phar.2012",
language = "English (US)",
volume = "37",
pages = "1197--1203",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "10",

}

TY - JOUR

T1 - Factors in Variability of Serial Gabapentin Concentrations in Elderly Patients with Epilepsy

AU - Conway, Jeannine M

AU - Eberly, Lynn E

AU - Collins, Joseph F.

AU - Macias, Flavia M.

AU - Ramsay, R. Eugene

AU - Leppik, Ilo E

AU - Birnbaum, Angela K

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Objectives: To characterize and quantify the variability of serial gabapentin concentrations in elderly patients with epilepsy. Methods: This study included 83 patients (age ≥ 60 yrs) from an 18-center randomized double-blind double-dummy parallel study from the Veterans Affairs Cooperative 428 Study. All patients were taking 1500 mg/day gabapentin. Within-person coefficient of variation (CV) in gabapentin concentrations, measured weekly to bimonthly for up to 52 weeks, then quarterly, was computed. Impact of patient characteristics on gabapentin concentrations (linear mixed model) and CV (linear regression) were estimated. Results: A total of 482 gabapentin concentration measurements were available for analysis. Gabapentin concentrations and intrapatient CVs ranged from 0.5 to 22.6 μg/ml (mean 7.9 μg/ml, standard deviation [SD] 4.1 μg/ml) and 2% to 79% (mean 27.9%, SD 15.3%), respectively, across all visits. Intrapatient CV was higher by 7.3% for those with a body mass index of ≥ 30 kg/m2 (coefficient = 7.3, p=0.04). CVs were on average 0.5% higher for each 1-unit higher CV in creatinine clearance (coefficient = 0.5, p=0.03) and 1.2% higher for each 1-hour longer mean time after dose (coefficient = 1.2, p=0.04). Conclusions: Substantial intrapatient variability in serial gabapentin concentration was noted in elderly patients with epilepsy. Creatinine clearance, time of sampling relative to dose, and obesity were found to be positively associated with variability.

AB - Objectives: To characterize and quantify the variability of serial gabapentin concentrations in elderly patients with epilepsy. Methods: This study included 83 patients (age ≥ 60 yrs) from an 18-center randomized double-blind double-dummy parallel study from the Veterans Affairs Cooperative 428 Study. All patients were taking 1500 mg/day gabapentin. Within-person coefficient of variation (CV) in gabapentin concentrations, measured weekly to bimonthly for up to 52 weeks, then quarterly, was computed. Impact of patient characteristics on gabapentin concentrations (linear mixed model) and CV (linear regression) were estimated. Results: A total of 482 gabapentin concentration measurements were available for analysis. Gabapentin concentrations and intrapatient CVs ranged from 0.5 to 22.6 μg/ml (mean 7.9 μg/ml, standard deviation [SD] 4.1 μg/ml) and 2% to 79% (mean 27.9%, SD 15.3%), respectively, across all visits. Intrapatient CV was higher by 7.3% for those with a body mass index of ≥ 30 kg/m2 (coefficient = 7.3, p=0.04). CVs were on average 0.5% higher for each 1-unit higher CV in creatinine clearance (coefficient = 0.5, p=0.03) and 1.2% higher for each 1-hour longer mean time after dose (coefficient = 1.2, p=0.04). Conclusions: Substantial intrapatient variability in serial gabapentin concentration was noted in elderly patients with epilepsy. Creatinine clearance, time of sampling relative to dose, and obesity were found to be positively associated with variability.

KW - antiseizure drug

KW - concentration

KW - elderly

KW - epilepsy

KW - gabapentin

KW - variability

UR - http://www.scopus.com/inward/record.url?scp=85031816297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031816297&partnerID=8YFLogxK

U2 - 10.1002/phar.2012

DO - 10.1002/phar.2012

M3 - Article

C2 - 28801938

AN - SCOPUS:85031816297

VL - 37

SP - 1197

EP - 1203

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 10

ER -